A. L. Erwin and R. J. Desnick, Congenital erythropoietic porphyria: Recent advances, Mol Genet Metab, 2018.

J. To-figueras, S. Ducamp, and J. Clayton, ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria, Blood, vol.118, issue.6, pp.1443-1451, 2011.

C. R. Bhasker, G. Burgiel, B. Neupert, A. Emery-goodman, L. C. Kühn et al., The putative iron-responsive element in the human erythroid 5-aminolevulinate synthase mRNA mediates translational control, J Biol Chem, vol.268, issue.17, pp.12699-705, 1993.

D. N. Egan, Z. Yang, J. Phillips, and J. L. Abkowitz, Inducing iron deficiency improves erythropoiesis and photosensitivity in congenital erythropoietic porphyria, Blood, vol.126, issue.2, pp.257-261, 2015.

R. P. Katugampola, A. V. Anstey, and A. Y. Finlay, A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases, Br J Dermatol, vol.167, issue.4, pp.888-900, 2012.

W. Xu, C. A. Warner, and R. J. Desnick, Congenital erythropoietic porphyria: identification and expression of 10 mutations in the uroporphyrinogen III synthase gene, J Clin Invest, vol.95, issue.2, pp.905-912, 1995.

A. Mirmiran, C. Schmitt, and T. Lefebvre, Erythroid-Progenitor-Targeted Gene Therapy Using Bifunctional TFR1 Ligand-Peptides in Human Erythropoietic Protoporphyria, Am J Hum Genet, vol.104, issue.2, pp.341-347, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02328937

S. Piomelli, M. B. Poh-fitzpatrick, C. Seaman, L. M. Skolnick, and W. E. Berdon, Complete Suppression of the Symptoms of Congenital Erythropoietic Porphyria by Long-Term Treatment with High-Level Transfusions, N Engl J Med, vol.314, issue.16, pp.1029-1031, 1986.

C. M. Peinado, C. Díaz-de-heredia, and J. To-figueras, Successful treatment of congenital erythropoietic porphyria using matched unrelated hematopoietic stem cell transplantation, Pediatr Dermatol, vol.30, issue.4, pp.484-489, 2013.

G. J. Kontoghiorghes and C. N. Kontoghiorghe, Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes, Drug Des Devel Ther, 2016.

V. Naessens, R. Ward, and K. Kuo, A proposed treatment algorithm for adults with Haemoglobin SC disease, Br J Haematol, vol.182, issue.4, pp.607-609, 2018.

F. Lionnet, N. Hammoudi, and K. S. Stojanovic, Hemoglobin sickle cell disease complications: A clinical study of 179 cases, Haematologica, vol.97, issue.8, pp.1136-1141, 2012.

R. P. Katugampola, M. N. Badminton, and A. Y. Finlay, Congenital erythropoietic porphyria: A single-observer clinical study of 29 cases, Br J Dermatol, vol.167, issue.4, pp.901-913, 2012.

J. Barman-aksözen, E. I. Minder, C. Schubiger, G. Biolcati, and X. Schneider-yin, In ferrochelatase-deficient protoporphyria patients, ALAS2 expression is enhanced and erythrocytic protoporphyrin concentration correlates with iron availability, Blood Cells, Mol Dis, vol.54, issue.1, pp.71-77, 2015.

A. C. Deacon and G. H. Elder, Front line tests for the investigation of suspected porphyria, J Clin Pathol, vol.54, issue.7, pp.500-507, 2001.